Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 116, Issue 12, Pages 3090-3100Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI30163
Keywords
-
Categories
Funding
- NCRR NIH HHS [M01 RR00040, M01 RR000040] Funding Source: Medline
- NHLBI NIH HHS [R37 HL055323, HL22633, HL62250, R01 HL055323, P01 HL022633, HL55323, HL70128, P01 HL062250, P01 HL059407, P50 HL070128, HL59407] Funding Source: Medline
- NIDDK NIH HHS [DK06990, R01 DK059533, DK59533] Funding Source: Medline
Ask authors/readers for more resources
HDL metabolism represents a major target for the development of therapies intended to reduce the risk of atherosclerotic cardiovascular disease. HDL metabolism is complex and involves dissociation of HDL apolipoprotein and HDL cholesterol metabolism. Advances in our under standing of the molecular regulation of HDL metabolism, macrophage cholesterol efflux, and HDL function will lead to a variety of novel therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available